Expertise in
18
conditions

Dr. Brian R. Hu

Urology
Faculty Physicians And Surgeons Of Llusm
26780 Barton Rd, 
Redlands, CA 
Offers Telehealth
Expertise in
18
conditions
Faculty Physicians And Surgeons Of Llusm
26780 Barton Rd, 
Redlands, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Brian Hu is an Urologist in Redlands, California. Dr. Hu is highly rated in 18 conditions, according to our data. His top areas of expertise are Bladder Cancer, Testicular Cancer, Urothelial Cancer, Cystectomy, and Nephrectomy.

His clinical research consists of co-authoring 48 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Urology
Licenses
Urology in CA
Hospital Affiliations
Loma Linda University Medical Center
Arrowhead Regional Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

FACULTY PHYSICIANS AND SURGEONS OF LLUSM
26780 Barton Rd, Redlands, CA 92373
Other Locations
FACULTY PHYSICIANS AND SURGEONS OF LLUSM
901 San Bernardino Rd, Suite 104and302, Upland, CA 91786
FACULTY PHYSICIANS AND SURGEONS OF LLUSM
11370 Anderson St, Loma Linda, CA 92354
FACULTY PHYSICIANS AND SURGEONS OF LLUSM
11234 Anderson St, Loma Linda, CA 92354

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 26, 2025
Intervention Type: Procedure, Other
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
Enrollment Status: Active_not_recruiting
Publish Date: November 04, 2024
Intervention Type: Drug
Study Drug: UGN-102
Study Phase: Phase 3
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Enrollment Status: Terminated
Publish Date: June 06, 2024
Intervention Type: Drug, Procedure
Study Drug: Mitomycin C
Study Phase: Phase 3
Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma With Isolated Retroperitoneal Disease (1-3cm)
Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma With Isolated Retroperitoneal Disease (1-3cm)
Enrollment Status: Active_not_recruiting
Publish Date: March 18, 2024
Intervention Type: Procedure, Other
Study Phase: Not Applicable
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Phase 3
Efficacy of Continuous Infusion of Local Anesthesia After Radical Cystectomy: A Randomized, Double Blind, Placebo Controlled Study
Efficacy of Continuous Infusion of Local Anesthesia After Radical Cystectomy: A Randomized, Double Blind, Placebo Controlled Study
Enrollment Status: Withdrawn
Publish Date: April 16, 2019
Intervention Type: Other, Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

48 Total Publications

Accuracy of 18F-FDG PET in Early Metastatic Testicular Seminoma: Analysis from the SEMS Trial.
Accuracy of 18F-FDG PET in Early Metastatic Testicular Seminoma: Analysis from the SEMS Trial.
Journal: The Journal of urology
Published: April 09, 2025
Similar Doctors
Expertise in
43
conditions
Dr. Siamak Daneshmand
Urology
Expertise in
43
conditions
Dr. Siamak Daneshmand
Urology

USC Care Medical Group Inc

1520 San Pablo St, 
Los Angeles, CA 
 (56.3 mi)
800-872-2273
Languages Spoken:
English
Offers Telehealth

Siamak Daneshmand is an Urologist in Los Angeles, California. Dr. Daneshmand is highly rated in 43 conditions, according to our data. His top areas of expertise are Bladder Cancer, Testicular Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Bladder Reconstruction.

Expertise in
37
conditions
Dr. Mihir M. Desai
Urology
Expertise in
37
conditions
Dr. Mihir M. Desai
Urology

USC Care Medical Group Inc

1812 Verdugo Blvd, 
Glendale, CA 
 (58.0 mi)
818-790-7100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mihir Desai is an Urologist in Glendale, California. Dr. Desai is highly rated in 37 conditions, according to our data. His top areas of expertise are Bladder Cancer, Enlarged Prostate (BPH), Renal Cell Carcinoma (RCC), Aquablation, and Nephrectomy.

Expertise in
43
conditions
Dr. Hooman Djaladat
Urology
Expertise in
43
conditions
Dr. Hooman Djaladat
Urology

USC Care Medical Group Inc

1500 San Pablo St, 
Los Angeles, CA 
 (56.2 mi)
323-442-8444
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hooman Djaladat is an Urologist in Los Angeles, California. Dr. Djaladat is highly rated in 43 conditions, according to our data. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), Cystectomy, and Nephrectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hu's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 31 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile